3rd phase clinical trial of India's dengue vaccine initiated
Wednesday, 14 August 2024 India's first phase-three trial for an indigenous tetravalent dengue vaccine, DengiALL, was initiated by Panacea Biotec. Conducted across 19 sites, the trial involves over 10,335 healthy adults. The vaccine aims to address all four dengue serotypes. The Union Health Minister J P Nadda highlighted its significance in combating dengue and enhancing India's vaccine development capabilities.
Tune in for comprehensive coverage of the closing submissions in the high-profile criminal trial of Tamara Lich and Chris Barber. As the trial enters its critical final phase, our coverage will dissect the pivotal moments and legal arguments presented during several days of intense closing...
Wednesday, 14 August 2024
